cutaneous neuroendocrine carcinoma
MONDO:0019210
Cutaneous neuroendocrine carcinoma is a primary cutaneous cancer arising from a subset of skin neuroendocrine cells (Merkel cells, giving the name Merkel cell carcinoma (MCC)).
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Merkel-cell carcinoma
Merkel cell carcinoma (MCC) is an aggressive skin cancer occurring in about three thousand persons per year in the United States. It is also known as cutaneous APUDoma, primary neuroendocrine carcinoma of the skin, primary small-cell carcinoma of the skin, and trabecular carcinoma of the skin. Factors involved in the development of MCC include the Merkel cell polyomavirus (MCPyV or MCV), a weakened immune system, or exposure to ultraviolet radiation. Merkel cell carcinoma usually arises on the head, neck, and extremities, as well as in the perianal region and on the eyelid. It ‘most often presents in an older white population with a male predominance'; 'median age of presentation falls within the late seventh decade, despite a broad age range (fourth to tenth decades).’ MCC is less common in children.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownDrugs being studied
Research locations
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.